Fig. 2

Correlation of SLC25A13 expression with tumor mutational burden (TMB), microsatellite Instability (MSI), and immune profiles in diverse cancers. Statistical significance is denoted as follows: ns (not significant, p > 0.05), *(p < 0.05), **(p < 0.01), ***(p < 0.001), and **** (p < 0.0001). A Spearman correlation between SLC25A13 expression and TMB across multiple cancer types. B Spearman correlation between SLC25A13 expression and MSI across various cancer types. C Univariate Cox survival analysis showing hazard ratios for overall survival associated with SLC25A13 expression in different cancer types. D Proportion of patients with high and low SLC25A13 expression, stratified by median SLC25A13 expression levels, across different immune subtypes as classified by The Immune Landscape of Cancer. E Spearman correlation between SLC25A13 expression and different immune cell infiltration fractions calculated by the CIBERSORT algorithm in multiple cancers. F Spearman correlation between SLC25A13 expression and various immune suppressive molecules. G Potential protein–protein interactions involving SLC25A13 identified from the ComPPI database. H Spearman correlation between SLC25A13 expression and scores calculated by the ESTIMATE algorithm in multiple cancers